Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 7/20 | 0.34 |
| ▸ | DRD3 | P35462 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822906 | 0.95 | MAPK1 (0.37) | MAPK1NAMPTCXCR2DRD2DRD3 | |
| SCHEMBL13437620 | 0.75 | DRD2 (0.45) | MAPK1DRD2DRD3LMNADRD1 | |
| SCHEMBL1820473 | 0.73 | SCN9A (0.43) | — | |
| SCHEMBL3584598 | 0.72 | CXCR2 (0.47) | CXCR2HSD11B1CXCR1 | |
| SCHEMBL3582529 | 0.70 | CXCR2 (0.45) | MAPK1CXCR2ADORA1HSD11B1CXCR1 | |
| SCHEMBL3575188 | 0.70 | CXCR2 (0.58) | MAPK1CXCR2HSD11B1CXCR1 | |
| SCHEMBL3576230 | 0.69 | CXCR2 (0.50) | CXCR2DRD2DRD3HSD11B1CXCR1 | |
| SCHEMBL1819925 | 0.69 | CXCR2 (0.48) | CXCR2DRD2DRD3HSD11B1CXCR1 | |
| SCHEMBL3574727 | 0.69 | CXCR2 (0.48) | CXCR2DRD2DRD3HSD11B1CXCR1 | |
| SCHEMBL3582579 | 0.69 | CXCR2 (0.48) | CXCR2DRD2DRD3HSD11B1CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2012-12-13 | — | — | US | claimed |
| EP-2493846-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe S.p.A. (IT) | 2012-09-05 | — | — | EP | claimed |
| WO-2011051375-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2011-05-05 | — | — | WO | claimed |
| EP-2316820-A1 | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2011-05-04 | — | — | EP | claimed |
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2012-12-13 | — | — | US | disclosed |
| EP-2493846-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe S.p.A. (IT) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051375-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.p.A. (IT) | 2011-05-05 | — | — | WO | disclosed |
| EP-2316820-A1 | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2011-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316169-A1 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BDKRB2, BDKRB1, CNR2 | MAPK1 494/4885NAMPT 1731/4885CXCR2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.